Protein Summary
Integrin alpha-9/beta-1 (ITGA9:ITGB1) is a receptor for VCAM1, cytotactin and osteopontin. It recognizes the sequence A-E-I-D-G-I-E-L in cytotactin. This gene encodes an alpha integrin. Integrins are heterodimeric integral membrane glycoproteins composed of an alpha chain and a beta chain that mediate cell-cell and cell-matrix adhesion. The protein encoded by this gene, when bound to the beta 1 chain, forms an integrin that is a receptor for VCAM1, cytotactin and osteopontin. Expression of this gene has been found to be upregulated in small cell lung cancers. [provided by RefSeq, Jul 2008]
- ENST00000264741
- ENSP00000264741
- ENSG00000144668
- RLC
- ITGA4L
- ALPHA-RLC
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
PubMedID | 0.88 | ||
transcription factor perturbation | 0.8 | ||
protein domain | 0.73 | ||
protein complex | 0.69 | ||
phenotype | 0.67 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 71.89 (req: < 5)
Gene RIFs: 52 (req: <= 3)
Antibodies: 185 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 71.89 (req: >= 5)
Gene RIFs: 52 (req: > 3)
Antibodies: 185 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 8
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0